Glucagon receptor agonism.
Engaging the glucagon receptor to raise energy expenditure and mobilise liver fat.
Glucagon is the counter-regulatory partner to insulin, released from pancreatic alpha cells when blood glucose falls. Its receptor is a class B G-protein-coupled receptor concentrated in the liver, with additional expression in kidney, heart, and adipose tissue. Classical glucagon signalling raises blood glucose by driving glycogen breakdown and gluconeogenesis in the liver, which on its face makes it a strange thing to activate deliberately in someone with a metabolic disorder. The rationale rests on glucagon's other actions. Glucagon receptor signalling in the liver also promotes fatty-acid oxidation and reduces hepatic fat accumulation, and across the body it is associated with a rise in resting energy expenditure. In other words it increases the rate at which energy is burned rather than only the rate at which food is refused. Combining that with GLP-1 activity is intended to cancel the unwanted half of the effect: the GLP-1 arm suppresses appetite and improves glucose handling strongly enough to offset the glucose-raising tendency of the glucagon arm, leaving the energy expenditure and liver fat benefits behind. Compounds here take different routes to the same idea. Some are rationally designed multi-agonists built to hit a specific ratio across two or three receptors. Others are derived from oxyntomodulin, a naturally occurring gut hormone that already engages both the GLP-1 and glucagon receptors, and are then modified for stability and duration. The balance between the two arms is the central design variable, and it differs meaningfully between agents. A molecule weighted more heavily toward glucagon may do more for liver fat while demanding more careful attention to glucose. This is a less mature pathway than GLP-1 agonism. No glucagon-receptor-containing agent has the depth of approved-medicine history that pure GLP-1 agonists have, and several of the compounds listed here are still in clinical development rather than in general use. The underlying physiology of glucagon is well established, and the metabolic logic of combining it with an incretin is coherent, but the long-term consequences of chronically raising glucagon signalling in people, including effects on glucose control and cardiovascular parameters over years, are still being worked out. It is also worth noting that the amount of glucagon activity a molecule carries is a design choice made in the laboratory, not something a user can adjust, so comparisons between agents in this class are comparisons between fixed ratios rather than between adjustable ones.
Peptides acting through this pathway.
FAQ.
What does glucagon receptor agonism do?
Glucagon is the counter-regulatory partner to insulin, released from pancreatic alpha cells when blood glucose falls. Its receptor is a class B G-protein-coupled receptor concentrated in the liver, with additional expression in kidney, heart, and adipose tissue. Classical glucagon signalling raises blood glucose by driving glycogen breakdown and gluconeogenesis in the liver, which on its face makes it a strange thing to activate deliberately in someone with a metabolic disorder. The rationale rests on glucagon's other actions. Glucagon receptor signalling in the liver also promotes fatty-acid oxidation and reduces hepatic fat accumulation, and across the body it is associated with a rise in resting energy expenditure. In other words it increases the rate at which energy is burned rather than only the rate at which food is refused. Combining that with GLP-1 activity is intended to cancel the unwanted half of the effect: the GLP-1 arm suppresses appetite and improves glucose handling strongly enough to offset the glucose-raising tendency of the glucagon arm, leaving the energy expenditure and liver fat benefits behind. Compounds here take different routes to the same idea. Some are rationally designed multi-agonists built to hit a specific ratio across two or three receptors. Others are derived from oxyntomodulin, a naturally occurring gut hormone that already engages both the GLP-1 and glucagon receptors, and are then modified for stability and duration. The balance between the two arms is the central design variable, and it differs meaningfully between agents. A molecule weighted more heavily toward glucagon may do more for liver fat while demanding more careful attention to glucose. This is a less mature pathway than GLP-1 agonism. No glucagon-receptor-containing agent has the depth of approved-medicine history that pure GLP-1 agonists have, and several of the compounds listed here are still in clinical development rather than in general use. The underlying physiology of glucagon is well established, and the metabolic logic of combining it with an incretin is coherent, but the long-term consequences of chronically raising glucagon signalling in people, including effects on glucose control and cardiovascular parameters over years, are still being worked out. It is also worth noting that the amount of glucagon activity a molecule carries is a design choice made in the laboratory, not something a user can adjust, so comparisons between agents in this class are comparisons between fixed ratios rather than between adjustable ones.
Which peptides act through glucagon receptor agonism?
Retatrutide, Survodutide, Mazdutide. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.